Neutrophil-to-mean platelet volume ratio as a new predictor for overall and cancer-specific survival in patients with localized clear cell renal cell carcinoma.
biomarker
neutrophil
neutrophil-to-mean platelet volume ratio
platelets
renal cell carcinoma
Journal
Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
12
2018
accepted:
08
02
2019
entrez:
1
9
2020
pubmed:
25
3
2019
medline:
25
3
2019
Statut:
epublish
Résumé
The present study investigated the prognostic value of neutrophil-to-mean platelet volume ratio (NMPVR) for overall (OS) and cancer-specific survival (CSS) in patients treated with nephrectomy for localized clear cell renal cell carcinoma (ccRCC). Medical records of 344 consecutive patients who underwent partial or radical nephrectomy for M0 ccRCC were retrospectively analyzed. Based on the median NMPVR, the study population was divided into two groups: the high NMPVR group with NMPVR higher than or equal to the median, and the low NMPVR group with NMPVR lower than the median. Comparisons of baseline characteristics and laboratory and pathological findings were performed. Kaplan-Meier survival curves and Cox regression model analysis were used to assess the prognostic value of the NMPVR. Patients with higher NMPVR values were more frequently diagnosed with advanced disease, tumor necrosis and higher tumor grade. The OS and CSS were significantly shorter in patients with NMPVR ≥ 0.41 compared to patients with NMPVR < 0.41. Inclusion of NMPVR in multivariable models of OS and CSS with other confounding variables determined categorized NMPVR as an independent prognostic factor for both endpoints. Pretreatment NMPVR ≥ 0.41 was associated with lower OS and CSS. NMPVR might be applied as a cheap and uncomplicated prognostic indicator in localized ccRCC patients treated with a primary surgical approach.
Identifiants
pubmed: 32863996
doi: 10.5114/aoms.2019.83822
pii: 36137
pmc: PMC7444721
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1072-1077Informations de copyright
Copyright: © 2019 Termedia & Banach.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Oncotarget. 2016 Nov 15;7(46):74886-74894
pubmed: 27713124
Cancer Metastasis Rev. 2014 Mar;33(1):231-69
pubmed: 24696047
Arch Med Sci. 2017 Oct;13(6):1249-1254
pubmed: 29181054
Cancer Biomark. 2018;22(3):559-563
pubmed: 29843218
Int J Mol Sci. 2017 Oct 20;18(10):
pubmed: 29053609
Curr Pharm Des. 2011;17(1):47-58
pubmed: 21247392
Nat Rev Urol. 2010 May;7(5):245-57
pubmed: 20448658
Br J Cancer. 2006 Sep 18;95(6):691-8
pubmed: 16940978
Biomed Res Int. 2016;2016:8687575
pubmed: 28105437
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Arch Med Sci. 2017 Apr 1;13(3):677-685
pubmed: 28507586
J Clin Oncol. 2006 May 1;24(13):1997-2005
pubmed: 16648500
Asian Pac J Cancer Prev. 2015;16(13):5305-10
pubmed: 26225670
Oncotarget. 2016 Dec 6;7(49):81849-81861
pubmed: 27833087
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
Nat Rev Urol. 2014 Sep;11(9):517-25
pubmed: 25112856
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Blood. 2000 Dec 15;96(13):4216-21
pubmed: 11110694
Trends Immunol. 2009 Nov;30(11):522-30
pubmed: 19775938
Hepatogastroenterology. 2004 May-Jun;51(57):847-53
pubmed: 15143932
Lung Cancer. 2014 Jan;83(1):97-101
pubmed: 24189108
Sci Rep. 2017 Jul 27;7(1):6700
pubmed: 28751781
Clin Genitourin Cancer. 2016 Feb;14(1):e1-8
pubmed: 26341038
Thromb Res. 2016 Mar;139:65-76
pubmed: 26916298
Bratisl Lek Listy. 2001;102(1):5-14
pubmed: 11723675
J Obstet Gynaecol Res. 2012 Apr;38(4):651-7
pubmed: 22413879
Asian Pac J Cancer Prev. 2016;17(9):4433-4437
pubmed: 27797257
J Urol. 2017 Dec;198(6):1247-1252
pubmed: 28716649
J Support Oncol. 2007 Apr;5(4):157-62; discussion 164-6, 183
pubmed: 17500503
Semin Immunol. 2016 Dec;28(6):535
pubmed: 27964804
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878